ROCKVILLE, Md., Oct. 22 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that it will present five posters on the pharmacogenetics of iloperidone at the 57th American Society of Human Genetics (ASHG) annual meeting to be held in San Diego, CA, from October 23 through October 27, 2007. This announcement follows the submission of the NDA filing for iloperidone on September 27, 2007. Iloperidone is an investigational atypical antipsychotic for the treatment of schizophrenia.
The following posters will be presented on Thursday, October 25, 2007, from 4:30 p.m. to 6:30 p.m. PDT, at the San Diego Convention Center.
POSTER 1035 - Whole Genome Association Study Identifies Polymorphisms in
the NPAS3 Gene Associated with Enhanced Response to
Iloperidone Treatment in Patients with Schizophrenia
POSTER 1036 - Pharmacogenetic Study of Iloperidone Treatment in Patients
with Schizophrenia Identifies Markers Associated with
POSTER 1037 - Pharmacogenetic Analysis Shows Differences in Markers
Associated with Response Between Two Atypical
Antipsychotics, Iloperidone and Ziprasidone, in the
Treatment of Patients with Schizophrenia
POSTER 1039 - Whole Genome Association Study Identifies Polymorphisms in
the CERKL Gene Associated with QT Prolongation during
Iloperidone Treatment of Patients with Schizophrenia
POSTER 1040 - Single-Nucleotide Polymorphisms in the CYP2D6 Gene Are
Correlated with Iloperidone Drug Exposure Levels, Affecting
|SOURCE Vanda Pharmaceuticals Inc.|
Copyright©2007 PR Newswire.
All rights reserved